Research translation doesn't happen by accident.

It requires great ideas, strong partnerships, commercial capability and a willingness to engage with opportunities beyond the lab.

This quarter reflects that journey in action. A new international partnership will help accelerate a promising UQ and QEDDI-developed prostate cancer therapy toward the clinic, while advances in livestock breeding, global engagement at BIO 2026 and strong demand for programs such as SPARK at UQ demonstrate the breadth and strength of UQ's innovation pipeline.

We're pleased to share a snapshot of that momentum with you.

Pictured (L to R): Head of QEDDI Dr Brian Dymock, Senior Drug Discovery Scientist Dr Mei-Chun Yeh, Medicinal Chemistry Team Leader Dr Rebecca Pouwer and Drug Discovery Team Leader Dr Kimberley Beaumont developed QED-203.

A promising prostate cancer therapy developed from research at The University of Queensland is a step closer to patients following an international licensing agreement between UniQuest and Los Angeles-based Ellison Medical Institute (EMI).

The agreement will accelerate development of QED-203, a potential first-in-class treatment for metastatic castration-resistant prostate cancer, a form of the disease where treatment options can become limited once existing therapies stop working.

Based on research led by Professor Greg Monteith from UQ's School of Pharmacy and Pharmaceutical Sciences, QED-203 was advanced through UniQuest's Queensland Emory Drug Discovery Initiative (QEDDI), highlighting the role of dedicated drug discovery and translation capability in progressing university research toward clinical impact.

The partnership positions QED-203 to advance toward first-in-human studies in 2027, drawing on EMI's expertise in translational medicine, oncology research and clinical development.
 

BIO International Conference 2026: Signals from the market 

Drawing on more than 55 formal conversations with pharmaceutical companies, biotech firms and investors at BIO 2026 (and countless informal ones), here are five signals shaping the future of research translation.
 

If there's one message UniQuest heard repeatedly at BIO 2026 it's that industry partners increasingly want evidence from human systems earlier in the translation journey. Patient samples, biomarkers, omics datasets and human tissue validation are becoming increasingly important in attracting commercial and investment interest.

What it means for researchers: Consider early how human-relevant evidence might strengthen the translational potential of your research.
 

AI was a consistent theme throughout the conference, with companies increasingly using AI to accelerate target discovery, prioritise experiments and inform decision-making. The focus is shifting from whether AI can help, to where it can create the most value in R&D.

What it means for researchers: AI is increasingly becoming part of the translational toolkit. Researchers who understand where it can add value may gain advantages in speed and efficiency.
 

The next generation of antibody therapeutics is moving beyond traditional monoclonal antibodies. Industry attention is increasingly focused on bispecific and trispecific antibodies, T-cell engagers and antibody-drug conjugates that can deliver more targeted therapeutic effects.

What it means for researchers: Differentiation is becoming just as important as the biological target itself.
 

Emerging technologies such as spatial biology, multi-omics and organoids continue to generate strong interest, but partners are looking for more than a compelling technology. Clear biological insights, strong drug target validation and a pathway to patient impact remain critical.

What it means for researchers: The strongest opportunities combine scientific excellence with a clear translational narrative.
 

The conference highlighted growing interest in therapies that address the underlying drivers of disease, rather than managing symptoms alone. For example, in the area of immunology, attention is increasingly turning to approaches that aim to restore immune function and deliver durable long-term outcomes.

What it means for researchers: Translational opportunities increasingly sought by companies and investors intercept the biological drivers of disease, rather than modify or dampen the symptoms.
 

Hot takes

• Backing big ideas: The UniQuest Extension Fund (UEF) has grown to a $44 million fund, supporting founders with a link to UQ and helping research-backed ventures grow from idea to impact. The milestone follows several successful investments and exits since the UEF launched in 2022. Read more.

• Sound investment: UQ startup Cortisonic has been selected for the Cicada x Tech23 cohort. The company is developing sonic processing technology that could dramatically reduce power consumption in edge computing environments. Read the LinkedIn post.

• From lab to clinic: UQ spinout NuNerve featured on ABC Radio Brisbane discussing its quest to develop a new treatment for motor neurone disease. Founded on research from Queensland Brain Institute, the company is preparing for its next clinical milestone following promising Phase 1 trial results. Read the LinkedIn post.

• A jab well done: As the 20th anniversary of Gardasil approaches in August, revisit the remarkable story behind the HPV vaccine developed by UQ Emeritus Professor Ian Frazer AC and Dr Jian Zhou. In Imagine IP's creative video, Sinth Jegaskanda retells how a breakthrough discovery evolved into a vaccine helping countries move towards eliminating cervical cancer. Watch the Imagine IP video on LinkedIn.

• Building pathways to impact: More than 100 UQ researchers attended UniQuest's annual Research Commercialisation Workshop in July, exploring pathways to licensing, startups and industry engagement. The event also marked the debut of the SHAPE Maker stream, supporting researchers in the social sciences, humanities and arts to explore new pathways to research translation. View the workshop highlights and SHAPE Maker pilot on LinkedIn.

• Quantum leap: UniQuest's Physical Sciences team showcased a pipeline of UQ technologies at the Quantum Australia Conference, spanning quantum computing, advanced imaging, next-generation displays and nano-phononic computing. The tech highlights the growing influence of Australian quantum and physical sciences research on global industry challenges. Read more.

Vedant Bharat

Senior Associate, Commercialisation - Physical Sciences

Vedant spent his formative years growing up in New Delhi, India before moving to Auckland, New Zealand, for high school. This international upbringing fostered a natural ability to empathise with different perspectives, a skill he finds essential when navigating the complexities of commercialisation and communicating value to diverse stakeholders.

He holds a BSc in Physiology and a Master of Bioscience Enterprise from the University of Auckland. His passion for the commercialisation journey was ignited while working as a consultant, where he had the opportunity to shadow a CEO during the intense, high-stakes process of capital raising. 

"That experience solidified my desire to lead and be at the forefront of bringing innovation to market," he said.

Vedant worked in commercialisation and IP management roles at JCU and Swinburne before moving to UniQuest to channel his experience into the physical sciences. Vedant thrives on the "win-win" nature of deal-making, and while he is a dedicated strategist who always looks for the advantage, he approaches every negotiation with a competitive spirit that keeps the process both dynamic and rewarding.

Outside the office, you'll find him cooking, obsessing over his chess elo rating, or trying to drag his cricket batting average north of 25. He finds the patience and strategy needed for these hobbies translate perfectly to his work.

"It's all about reading the game, anticipating the next move, and knowing exactly when to go for the win," he said.

UniQuest acknowledges the Traditional Owners and their custodianship of the lands on which The University of Queensland and UniQuest are situated.
We pay our respects to their Ancestors and their descendants, who continue cultural and spiritual connections to Country. ​​We recognise their valuable contributions to Australian and global society.